Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Votes To Limit ESA Cancer Use To Metastatic Patients

Executive Summary

Following the recommendations of its Oncologic Drugs Advisory Committee, FDA's next step in ensuring the safe use of erythropoiesis-stimulating agents will be to determine how best to narrow the approved indication for anemia treatment in the cancer setting
Advertisement

Related Content

FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
All-Amgen Denosumab Raises Hopes; Proof-Of-Concept Peek Due At ASCO
All-Amgen Denosumab Raises Hopes; Proof-Of-Concept Peek Due At ASCO
Aranesp, Procrit Face New Headwind With Tumor-Specific Restrictions
Aranesp, Procrit Face New Headwind With Tumor-Specific Restrictions
Amgen Plans Seven ESA Risk Studies After Latest Safety Update To Labeling
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Advertisement
UsernamePublicRestriction

Register

PS049406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel